My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 106

    1.

    Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.

    Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, Penichet ML.

    Breast Cancer Res. 2009;11(3):R36. Epub 2009 Jun 16.PMID: 19531256 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2).

    Gonzalez RR, Cherfils S, Escobar M, Yoo JH, Carino C, Styer AK, Sullivan BT, Sakamoto H, Olawaiye A, Serikawa T, Lynch MP, Rueda BR.

    J Biol Chem. 2006 Sep 8;281(36):26320-8. Epub 2006 Jul 6.PMID: 16825198 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status.

    Ray A, Nkhata KJ, Cleary MP.

    Int J Oncol. 2007 Jun;30(6):1499-509.PMID: 17487372 [PubMed - indexed for MEDLINE]Related articles

    4.

    Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.

    Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC.

    Breast Cancer Res. 2008;10(1):R21. Epub 2008 Feb 29.PMID: 18312651 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

    Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R.

    J Natl Cancer Inst. 2004 Jun 16;96(12):926-35.PMID: 15199112 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.

    Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO, Kim SH, Lu J.

    Breast Cancer Res. 2007;9(6):R77.PMID: 17986353 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression.

    Applanat MP, Buteau-Lozano H, Herve MA, Corpet A.

    Adv Exp Med Biol. 2008;617:437-44.PMID: 18497067 [PubMed - indexed for MEDLINE]Related articles

    8.

    MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.

    Atanaskova N, Keshamouni VG, Krueger JS, Schwartz JA, Miller F, Reddy KB.

    Oncogene. 2002 Jun 6;21(25):4000-8.PMID: 12037682 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.

    Aesoy R, Sanchez BC, Norum JH, Lewensohn R, Viktorsson K, Linderholm B.

    Mol Cancer Res. 2008 Oct;6(10):1630-8.PMID: 18922978 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.

    Thoennissen NH, O'Kelly J, Lu D, Iwanski GB, La DT, Abbassi S, Leiter A, Karlan B, Mehta R, Koeffler HP.

    Oncogene. 2010 Jan 14;29(2):285-96. Epub 2009 Oct 26.PMID: 19855437 [PubMed - indexed for MEDLINE]Related articles

    11.

    Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.

    Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.

    Anticancer Res. 2006 May-Jun;26(3A):1773-84.PMID: 16827106 [PubMed - indexed for MEDLINE]Related articles

    12.

    Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.

    Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M.

    Cancer Res. 2002 Sep 1;62(17):4977-84.PMID: 12208749 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells.

    Lim JT, Joe AK, Suzui M, Shimizu M, Masuda M, Weinstein IB.

    Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3478-84.PMID: 16740773 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

    Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH.

    J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33.PMID: 14679152 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.

    Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S.

    PLoS Med. 2007 Jun;4(6):e186.PMID: 17550303 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.

    Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G.

    Clin Cancer Res. 2004 Jan 15;10(2):784-93.PMID: 14760102 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.

    Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D.

    Mol Endocrinol. 1999 May;13(5):787-96.PMID: 10319328 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Estrogen-related receptor-alpha antagonist inhibits both estrogen receptor-positive and estrogen receptor-negative breast tumor growth in mouse xenografts.

    Chisamore MJ, Wilkinson HA, Flores O, Chen JD.

    Mol Cancer Ther. 2009 Mar;8(3):672-81. Epub 2009 Mar 10.PMID: 19276159 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.

    Bartucci M, Morelli C, Mauro L, Andò S, Surmacz E.

    Cancer Res. 2001 Sep 15;61(18):6747-54.PMID: 11559546 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

    Rydén L, Jirström K, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Thorstenson S, Jönsson PE, Landberg G.

    J Clin Oncol. 2005 Jul 20;23(21):4695-704.PMID: 16034044 [PubMed - indexed for MEDLINE]Related articles

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    You are here: NCBI > Literature > PubMed
    Write to the Help Desk